KLOR-CON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KLOR-CON (KLOR-CON).
Potassium chloride acts as a source of potassium ions, which are essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium is the major cation of intracellular fluid and helps regulate acid-base balance.
| Metabolism | Potassium chloride is not metabolized; it is absorbed and excreted renally. |
| Excretion | Renal excretion of potassium ions accounts for approximately 90% of elimination via the kidneys, with the remaining 10% eliminated fecally. No biliary excretion is clinically significant. |
| Half-life | The terminal elimination half-life of potassium is approximately 1-1.5 hours in healthy individuals with normal renal function. In patients with impaired renal function, half-life may be prolonged, increasing the risk of hyperkalemia. |
| Protein binding | Potassium is not protein bound in plasma. Protein binding is < 1%. |
| Volume of Distribution | The apparent volume of distribution for potassium is approximately 0.4 L/kg (total body water), reflecting its distribution primarily in the intracellular space (>98% of total body potassium is intracellular). |
| Bioavailability | Oral bioavailability of potassium from KLOR-CON (potassium chloride) is complete (approximately 100%) as absorption is highly efficient across the gastrointestinal tract, assuming no malabsorption issues. |
| Onset of Action | For oral administration of KLOR-CON (potassium chloride), the onset of action is 30 minutes to 2 hours after ingestion, as the potassium begins to be absorbed across the gastrointestinal tract. For intravenous administration (not applicable to this product), onset is immediate. |
| Duration of Action | The duration of action after oral administration is approximately 6-8 hours, corresponding to the time needed for renal excretion of the administered potassium load. Individual effects on serum potassium levels may persist depending on ongoing losses and renal function. |
Potassium chloride extended-release: 20-100 mEq per day orally, divided into 2-4 doses, titrated based on serum potassium and clinical response. Usual starting dose: 40 mEq per day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 10-50 mL/min: Use with caution, reduce dose by 25-50% and monitor serum potassium frequently. GFR <10 mL/min: Avoid use as risk of hyperkalemia is high; consider alternative therapy. |
| Liver impairment | No specific dose adjustment for Child-Pugh class A or B; monitor serum potassium closely. Child-Pugh class C: Use with extreme caution due to risk of electrolyte disturbances; no established dose modification, start at lowest effective dose. |
| Pediatric use | Oral: 1-4 mEq/kg per day in divided doses, not to exceed 40 mEq per dose or 100 mEq per day. Intravenous: 0.5-1 mEq/kg per dose, infused over 1-2 hours, with ECG monitoring; maximum concentration 40 mEq/L. |
| Geriatric use | Start at low end of dosing range (20 mEq/day). Monitor renal function and serum potassium closely due to age-related decline in renal function and increased risk of hyperkalemia. Avoid potassium-sparing diuretics. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KLOR-CON (KLOR-CON).
| Breastfeeding | Potassium is a normal constituent of human milk; concentrations parallel maternal plasma levels. The M/P ratio is approximately 1.0. No adverse effects in breastfed infants have been reported. Use with caution, especially in mothers with renal impairment or on potassium-sparing diuretics. |
| Teratogenic Risk | Potassium chloride is not teratogenic in animal studies at doses up to 50 mg/kg/day. In humans, no increased risk of congenital anomalies has been reported with therapeutic use. However, maternal hypokalemia or hyperkalemia may adversely affect fetal development. Use only if clearly needed. |
■ FDA Black Box Warning
None. FDA does not require a black box warning for potassium chloride oral formulations.
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria or azotemia","Untreated Addison's disease","Acute dehydration","Heat cramps","Concomitant use with potassium-sparing diuretics or triamterene","Solid oral formulations in patients with esophageal compression or delayed GI transit"]
| Precautions | ["Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia.","Monitor serum potassium levels regularly.","Solid oral dosage forms can cause gastrointestinal lesions; use caution in patients with esophageal or GI tract obstruction.","Avoid use in patients with severe renal insufficiency or adrenal insufficiency."] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium, renal function, and ECG periodically. Observe for signs of hyperkalemia (e.g., muscle weakness, cardiac arrhythmias). During pregnancy, monitor fetal heart rate and growth if maternal electrolyte disturbances occur. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Hypokalemia or hyperkalemia may impair ovarian or testicular function, but no direct fertility impairment from potassium chloride is documented. |